ABT Quote, Financials, Valuation and Earnings

Boston Scientific Corp. has a net margin of 14.07% compared to Abbott Laboratories's net margin of 14.91%. Abbott Laboratories's return on equity of 29.06% beat Boston Scientific Corp.'s return on equity of 12.46%.

Abbott Laboratories has a consensus price target of $144.43, signalling upside risk potential of 15.28%. On the other hand Boston Scientific Corp. has an analysts' consensus of $126.48 which suggests that it could grow by 28.32%. Given that Boston Scientific Corp. has higher upside potential than Abbott Laboratories, analysts believe Boston Scientific Corp. is more attractive than Abbott Laboratories.

Abbott Laboratories has a beta of 0.716, which suggesting that the stock is 28.412% less volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.673, suggesting its less volatile than the S&P 500 by 32.691%.

Abbott Laboratories has a quarterly dividend of $0.59 per share corresponding to a yield of 1.88%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abbott Laboratories pays 29.33% of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Abbott Laboratories quarterly revenues are $11.4B, which are larger than Boston Scientific Corp. quarterly revenues of $5.1B. Abbott Laboratories's net income of $1.6B is higher than Boston Scientific Corp.'s net income of $755M. Notably, Abbott Laboratories's price-to-earnings ratio is 15.72x while Boston Scientific Corp.'s PE ratio is 52.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abbott Laboratories is 5.00x versus 7.61x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

DexCom, Inc. has a net margin of 14.07% compared to Abbott Laboratories's net margin of 23.47%. Abbott Laboratories's return on equity of 29.06% beat DexCom, Inc.'s return on equity of 30.94%.

Abbott Laboratories has a consensus price target of $144.43, signalling upside risk potential of 15.28%. On the other hand DexCom, Inc. has an analysts' consensus of $84.77 which suggests that it could grow by 30.72%. Given that DexCom, Inc. has higher upside potential than Abbott Laboratories, analysts believe DexCom, Inc. is more attractive than Abbott Laboratories.

Abbott Laboratories has a beta of 0.716, which suggesting that the stock is 28.412% less volatile than S&P 500. In comparison DexCom, Inc. has a beta of 1.513, suggesting its more volatile than the S&P 500 by 51.265%.

Abbott Laboratories has a quarterly dividend of $0.59 per share corresponding to a yield of 1.88%. DexCom, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abbott Laboratories pays 29.33% of its earnings as a dividend. DexCom, Inc. pays out -- of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Abbott Laboratories quarterly revenues are $11.4B, which are larger than DexCom, Inc. quarterly revenues of $1.2B. Abbott Laboratories's net income of $1.6B is higher than DexCom, Inc.'s net income of $283.8M. Notably, Abbott Laboratories's price-to-earnings ratio is 15.72x while DexCom, Inc.'s PE ratio is 36.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abbott Laboratories is 5.00x versus 5.85x for DexCom, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

EXACT Sciences Corp. has a net margin of 14.07% compared to Abbott Laboratories's net margin of -2.3%. Abbott Laboratories's return on equity of 29.06% beat EXACT Sciences Corp.'s return on equity of -38%.

Abbott Laboratories has a consensus price target of $144.43, signalling upside risk potential of 15.28%. On the other hand EXACT Sciences Corp. has an analysts' consensus of $103.67 which suggests that it could grow by 2.39%. Given that Abbott Laboratories has higher upside potential than EXACT Sciences Corp., analysts believe Abbott Laboratories is more attractive than EXACT Sciences Corp..

Abbott Laboratories has a beta of 0.716, which suggesting that the stock is 28.412% less volatile than S&P 500. In comparison EXACT Sciences Corp. has a beta of 1.417, suggesting its more volatile than the S&P 500 by 41.664%.

Abbott Laboratories has a quarterly dividend of $0.59 per share corresponding to a yield of 1.88%. EXACT Sciences Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abbott Laboratories pays 29.33% of its earnings as a dividend. EXACT Sciences Corp. pays out -- of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Abbott Laboratories quarterly revenues are $11.4B, which are larger than EXACT Sciences Corp. quarterly revenues of $850.7M. Abbott Laboratories's net income of $1.6B is higher than EXACT Sciences Corp.'s net income of -$19.6M. Notably, Abbott Laboratories's price-to-earnings ratio is 15.72x while EXACT Sciences Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abbott Laboratories is 5.00x versus 6.16x for EXACT Sciences Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 14.07% compared to Abbott Laboratories's net margin of 21.47%. Abbott Laboratories's return on equity of 29.06% beat Johnson & Johnson's return on equity of 33.27%.

Abbott Laboratories has a consensus price target of $144.43, signalling upside risk potential of 15.28%. On the other hand Johnson & Johnson has an analysts' consensus of $202.54 which suggests that it could fall by -1.36%. Given that Abbott Laboratories has higher upside potential than Johnson & Johnson, analysts believe Abbott Laboratories is more attractive than Johnson & Johnson.

Abbott Laboratories has a beta of 0.716, which suggesting that the stock is 28.412% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.296%.

Abbott Laboratories has a quarterly dividend of $0.59 per share corresponding to a yield of 1.88%. Johnson & Johnson offers a yield of 2.5% to investors and pays a quarterly dividend of $1.30 per share. Abbott Laboratories pays 29.33% of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Abbott Laboratories quarterly revenues are $11.4B, which are smaller than Johnson & Johnson quarterly revenues of $24B. Abbott Laboratories's net income of $1.6B is lower than Johnson & Johnson's net income of $5.2B. Notably, Abbott Laboratories's price-to-earnings ratio is 15.72x while Johnson & Johnson's PE ratio is 19.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abbott Laboratories is 5.00x versus 5.40x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.